Zhang M, Huang G, Bao X, Yang Q
BMC Nephrol. 2025; 26(1):46.
PMID: 39885381
PMC: 11780984.
DOI: 10.1186/s12882-025-03978-8.
Cai R, Li F, Li Y, Li Y, Peng W, Zhao M
Int J Cardiol Heart Vasc. 2024; 53:101434.
PMID: 38974459
PMC: 11225710.
DOI: 10.1016/j.ijcha.2024.101434.
Fuior E, Zvintzou E, Filippatos T, Giannatou K, Mparnia V, Simionescu M
Biomedicines. 2023; 11(10).
PMID: 37893070
PMC: 10604751.
DOI: 10.3390/biomedicines11102696.
Du X, Jiang Y, Sun Y, Cao X, Zhang Y, Xu Q
Int J Mol Sci. 2023; 24(19).
PMID: 37833910
PMC: 10573016.
DOI: 10.3390/ijms241914462.
Sun S, Chen L, Chen D, Li Y, Liu G, Ma L
Ther Adv Endocrinol Metab. 2023; 14:20420188231198620.
PMID: 37719790
PMC: 10501065.
DOI: 10.1177/20420188231198620.
A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad.
Yanai H, Adachi H, Hakoshima M, Katsuyama H
Cardiol Res. 2023; 14(2):158-160.
PMID: 37091888
PMC: 10116931.
DOI: 10.14740/cr1496.
New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds.
Yang B, Xin M, Liang S, Xu X, Cai T, Dong L
Front Pharmacol. 2022; 13:1026246.
PMID: 36483739
PMC: 9723165.
DOI: 10.3389/fphar.2022.1026246.
Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.
Gherghina M, Peride I, Tiglis M, Neagu T, Niculae A, Checherita I
Int J Mol Sci. 2022; 23(6).
PMID: 35328614
PMC: 8949471.
DOI: 10.3390/ijms23063188.
Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
Yanai H, Katsuyama H, Hakoshima M
Biomedicines. 2022; 10(2).
PMID: 35203610
PMC: 8962310.
DOI: 10.3390/biomedicines10020401.
A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
Yanai H, Katsuyama H, Hakoshima M
Cardiol Res. 2021; 12(6):358-362.
PMID: 34970366
PMC: 8683099.
DOI: 10.14740/cr1333.
Urate transport in health and disease.
Kuhns V, Woodward O
Best Pract Res Clin Rheumatol. 2021; 35(4):101717.
PMID: 34690083
PMC: 8678298.
DOI: 10.1016/j.berh.2021.101717.
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.
Ferreira J, Inzucchi S, Mattheus M, Meinicke T, Steubl D, Wanner C
Diabetes Obes Metab. 2021; 24(1):135-141.
PMID: 34558768
PMC: 9293326.
DOI: 10.1111/dom.14559.
Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
Yanai H, Adachi H, Hakoshima M, Katsuyama H
Int J Mol Sci. 2021; 22(17).
PMID: 34502127
PMC: 8431537.
DOI: 10.3390/ijms22179221.
Modulation of Urate Transport by Drugs.
Tatrai P, Erdo F, Dornyei G, Krajcsi P
Pharmaceutics. 2021; 13(6).
PMID: 34204277
PMC: 8235739.
DOI: 10.3390/pharmaceutics13060899.
Membrane Carriers and Transporters in Kidney Physiology and Disease.
Drozdzik M, Drozdzik M, Oswald S
Biomedicines. 2021; 9(4).
PMID: 33919957
PMC: 8070919.
DOI: 10.3390/biomedicines9040426.
Renal effects of uric acid: hyperuricemia and hypouricemia.
Park J, Jo Y, Lee J
Korean J Intern Med. 2020; 35(6):1291-1304.
PMID: 32872730
PMC: 7652664.
DOI: 10.3904/kjim.2020.410.
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Sun X, Liu J, Wang G
Lipids Health Dis. 2020; 19(1):103.
PMID: 32446306
PMC: 7245839.
DOI: 10.1186/s12944-020-01254-2.
Hypouricemia: what the practicing rheumatologist should know about this condition.
Pineda C, Soto-Fajardo C, Mendoza J, Gutierrez J, Sandoval H
Clin Rheumatol. 2019; 39(1):135-147.
PMID: 31650389
DOI: 10.1007/s10067-019-04788-8.
Effect of fenofibrate on uric acid level in patients with gout.
Jung J, Choi Y, Suh C, Yoon D, Kim H
Sci Rep. 2018; 8(1):16767.
PMID: 30425304
PMC: 6233215.
DOI: 10.1038/s41598-018-35175-z.
Fenofibrate Interferes with the Diapedesis of Lung Adenocarcinoma Cells through the Interference with Cx43/EGF-Dependent Intercellular Signaling.
Piwowarczyk K, Kwiecien E, Sosniak J, Zimolag E, Guzik E, Sroka J
Cancers (Basel). 2018; 10(10).
PMID: 30274176
PMC: 6210471.
DOI: 10.3390/cancers10100363.